Table 1. Surviving Fraction and Micronucleus Frequency at 0 Gy.

	Without thalidomide	With thalidomide (once)	With thalidomide (twice)
Surviving fraction at 0 Gy (%)
Without nicotinamide or mild temperature hyperthermia	84.4 ± 8.2a	60.0 ± 5.5	69.8 ± 6.3
With nicotinamide	81.4 ± 7.3	55.0 ± 4.3	60.0 ± 5.7
With mild temperature hyperthermia	83.5 ± 8.7	56.0 ± 5.9	60.5 ± 5.3
Micronucleus frequency at 0 Gy
Total tumor cell population
Without nicotinamide or mild temperature hyperthermia	0.050 ± 0.005	0.081 ± 0.008	0.070 ± 0.007
With nicotinamide	0.057 ± 0.006	0.090 ± 0.008	0.082 ± 0.008
With mild temperature hyperthermia	0.054 ± 0.005	0.085 ± 0.009	0.080 ± 0.008
Quiescent cells
Without nicotinamide or mild temperature hyperthermia	0.077 ± 0.007	0.102 ± 0.01	0.094 ± 0.009
With nicotinamide	0.084 ± 0.008	0.11 ± 0.01	0.101 ± 0.01
With mild temperature hyperthermia	0.081 ± 0.008	0.103 ± 0.01	0.099 ± 0.009

^aMean ± standard error (n = 6). Q cells showed significantly higher micronucleus frequencies than the total cell population under each set of conditions (P < 0.05). Thalidomide administration resulted in significantly lower surviving fractions and significantly higher micronucleus frequencies in both the total and Q cell populations than absolutely no treatment (P < 0.05).